Difluoromethylornithine chemoprevention of skin cancer in organ transplant recipients

Journal of Drugs in Dermatology, Jan, 2008

Sponsored by the University of Wisconsin. The purposes of this study are to determine if DFMO at 500 mg daily will be well-tolerated for 12 months and not affect organ transplant viability; will inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ornithine decarboxylase (ODC) in skin biopsies by approximately 50% for the 12 months of therapy; and will be able to decrease polyamine levels in skin biopsies for the 12 months of treatment.

Condition         Intervention                   Phase

Post-Solid Organ  Drug: Difluoromethylornithine  Phase II
  Transplant
Skin Neoplasms

Study ID Numbers: 2001-414, CO00318

ClinicalTrials.gov Identifier: NCT00204789